676 related articles for article (PubMed ID: 27678458)
1. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers for cancer therapy with PARP inhibitors.
Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
[TBL] [Abstract][Full Text] [Related]
5. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
8. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
9. Emerging PARP inhibitors for treating breast cancer.
Robert M; Patsouris A; Frenel JS; Gourmelon C; Augereau P; Campone M
Expert Opin Emerg Drugs; 2018 Sep; 23(3):211-221. PubMed ID: 30251552
[TBL] [Abstract][Full Text] [Related]
10. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies.
Gachechiladze M; Škarda J; Soltermann A; Joerger M
Int J Cancer; 2017 Oct; 141(7):1286-1294. PubMed ID: 28477336
[TBL] [Abstract][Full Text] [Related]
11. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
12. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
Helleday T
Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Brown JS; O'Carrigan B; Jackson SP; Yap TA
Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
[TBL] [Abstract][Full Text] [Related]
14. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
15. DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J; Tao Z; Cao J; Li T; Hu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
17. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
18. State-of-the-art strategies for targeting the DNA damage response in cancer.
Pilié PG; Tang C; Mills GB; Yap TA
Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
[TBL] [Abstract][Full Text] [Related]
19. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]